KOD

SEC source: 0001209191-20-043313 · doc4.xml · nonDerivative · entry 4

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,984

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $51.18 to $51.21, inclusive.

SEC source: 0001209191-20-043313 · doc4.xml · nonDerivative · entry 3

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,360

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $50.16 to $50.90, inclusive.

SEC source: 0001209191-20-043313 · doc4.xml · nonDerivative · entry 2

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,460

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $49.01 to $49.95, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes.

SEC source: 0001209191-20-043313 · doc4.xml · nonDerivative · entry 1

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,934

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001640147-20-000007 · primary_doc.xml · derivative · entry 2

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 393,425

Underlying: Common Stock · 2,700 shares

Expires 2028-08-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vested on September 1, 2019 and 1/48th of the shares subject to the option vest on the same day of each month thereafter.

SEC source: 0001640147-20-000007 · primary_doc.xml · nonDerivative · entry 1

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,984

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001638599-20-000650 · doc4_6782.xml · derivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 7,106

Underlying: Common Stock · 7,106 shares

Expires 2030-06-29

F1 · derivative.exercise_price: 7,106 non-qualified stock options ("Stock Options") exercisable solely into common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") were granted under the Issuer's 2018 Equity Incentive Plan to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") in his capacity as a director of the Issuer. The Stock Options with a strike price of $54.12, vest on the earlier of June 30, 2021 or one day prior to the Issuer's next annual meeting following the grant date.

F1 · derivative.exercise_date: 7,106 non-qualified stock options ("Stock Options") exercisable solely into common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") were granted under the Issuer's 2018 Equity Incentive Plan to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") in his capacity as a director of the Issuer. The Stock Options with a strike price of $54.12, vest on the earlier of June 30, 2021 or one day prior to the Issuer's next annual meeting following the grant date.

F1 · derivative.expiration_date: 7,106 non-qualified stock options ("Stock Options") exercisable solely into common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") were granted under the Issuer's 2018 Equity Incentive Plan to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") in his capacity as a director of the Issuer. The Stock Options with a strike price of $54.12, vest on the earlier of June 30, 2021 or one day prior to the Issuer's next annual meeting following the grant date.

F1 · ownership.nature: 7,106 non-qualified stock options ("Stock Options") exercisable solely into common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") were granted under the Issuer's 2018 Equity Incentive Plan to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") in his capacity as a director of the Issuer. The Stock Options with a strike price of $54.12, vest on the earlier of June 30, 2021 or one day prior to the Issuer's next annual meeting following the grant date.

F2 · ownership.nature: Felix J. Baker serves on the board of directors of the Issuer (the "Board") as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds"). Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Felix J. Baker does not have any right to any of the Issuer's securities issued as part of his service on the Board and the Funds are entitled to receive all of the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the Stock Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options and any Common Stock resulting from the exercise of Stock Options (i.e. no direct pecuniary interest).

F3 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Pursuant to agreements between Felix J. Baker and the Adviser, the Adviser has voting and dispositive power over the Stock Options, and any Common Stock received as a result of the exercise of Stock Options.

SEC source: 0001209191-20-040829 · doc4.xml · derivative · entry 1

PROFUSEK ROBERT · CIK 0001143732 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,106

Underlying: Common Stock · 7,106 shares

Expires 2030-06-29

F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2021 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date.

SEC source: 0001209191-20-040809 · doc4.xml · derivative · entry 1

PERLROTH VICTOR · CIK 0001754181 · Director · Chairman, President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 247,498

Underlying: Common Stock · 247,498 shares

Expires 2030-06-29

F1 · derivative.exercise_date: One-forty-eighth (1/48th) of the shares subject to the option vests in equal monthly installments over four years measured from June 30, 2020, subject to Reporting Person's continued service on the applicable vesting date.

SEC source: 0001209191-20-040817 · doc4.xml · derivative · entry 1

Bancroft Charles A · CIK 0001480250 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,104

Underlying: Common Stock · 2,104 shares

Expires 2030-06-29

F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2021 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date.

SEC source: 0001209191-20-040831 · doc4.xml · derivative · entry 1

Yang Taiyin · CIK 0001334505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,417

Underlying: Common Stock · 5,417 shares

Expires 2030-06-29

F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2021 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, provided the Reporting Person continues to serve as a member of the Issuer's Board through the applicable vesting date.

SEC source: 0001209191-20-040825 · doc4.xml · derivative · entry 1

Levy Richard S · CIK 0001454983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,106

Underlying: Common Stock · 7,106 shares

Expires 2030-06-29

F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2021 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date.

SEC source: 0001209191-20-040815 · doc4.xml · derivative · entry 2

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,476

Underlying: Common Stock · 14,476 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's common stock.

F3 · derivative.exercise_date: One-fourth (1/4th) of the restricted stock units vest on each of the first four anniversaries of June 15, 2020, subject to Reporting Person's continued service on the applicable vesting date.

F3 · derivative.expiration_date: One-fourth (1/4th) of the restricted stock units vest on each of the first four anniversaries of June 15, 2020, subject to Reporting Person's continued service on the applicable vesting date.

SEC source: 0001209191-20-040815 · doc4.xml · derivative · entry 1

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,163

Underlying: Common Stock · 46,163 shares

Expires 2030-06-29

F1 · derivative.exercise_date: One-forty-eighth (1/48th) of the shares subject to the option vests in equal monthly installments over four years measured from June 30, 2020, subject to Reporting Person's continued service on the applicable vesting date.

SEC source: 0001209191-20-040820 · doc4.xml · derivative · entry 1

Dahiyat Bassil I · CIK 0001591312 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,106

Underlying: Common Stock · 7,106 shares

Expires 2030-06-29

F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2021 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date.

SEC source: 0001209191-20-040811 · doc4.xml · derivative · entry 2

BORGESON JOHN A. · CIK 0001754045 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,476

Underlying: Common Stock · 14,476 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's common stock.

F3 · derivative.exercise_date: One-fourth (1/4th) of the restricted stock units vest on each of the first four anniversaries of June 15, 2020, subject to Reporting Person's continued service on the applicable vesting date.

F3 · derivative.expiration_date: One-fourth (1/4th) of the restricted stock units vest on each of the first four anniversaries of June 15, 2020, subject to Reporting Person's continued service on the applicable vesting date.

SEC source: 0001209191-20-040811 · doc4.xml · derivative · entry 1

BORGESON JOHN A. · CIK 0001754045 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,163

Underlying: Common Stock · 46,163 shares

Expires 2030-06-29

F1 · derivative.exercise_date: One-forty-eighth (1/48th) of the shares subject to the option vests in equal monthly installments over four years measured from June 30, 2020, subject to Reporting Person's continued service on the applicable vesting date.

SEC source: 0001209191-20-038752 · doc4.xml · derivative · entry 7

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 396,125

Underlying: Common Stock · 6,950 shares

Expires 2028-08-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vested on September 1, 2019 and 1/48th of the shares subject to the option vest on the same day of each month thereafter.

SEC source: 0001209191-20-038752 · doc4.xml · nonDerivative · entry 6

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,284

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $64.02 to $64.36, inclusive.

SEC source: 0001209191-20-038752 · doc4.xml · nonDerivative · entry 5

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,390

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $62.65 to $63.20, inclusive.

SEC source: 0001209191-20-038752 · doc4.xml · nonDerivative · entry 4

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,113

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $60.99 to $61.78, inclusive.

SEC source: 0001209191-20-038752 · doc4.xml · nonDerivative · entry 3

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,758

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $59.98 to $60.93, inclusive.

SEC source: 0001209191-20-038752 · doc4.xml · nonDerivative · entry 2

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,442

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $58.89 to $59.89, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes.

SEC source: 0001209191-20-038752 · doc4.xml · nonDerivative · entry 1

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,234

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001638599-20-000595 · doc4_6754.xml · derivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,135

Underlying: Common Stock · 4,135 shares

Expires 2030-06-07

F1 · derivative.exercise_date: 4,135 non-qualified stock options ("Stock Options") exercisable solely into common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") were granted under the Issuer's 2018 Equity Incentive Plan to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") in his capacity as a director of the Issuer. The Stock Options with a strike price of $62.50, vest on the earlier of June 8, 2021 or one day prior to the Issuer's next annual meeting following the grant date.

F1 · ownership.nature: 4,135 non-qualified stock options ("Stock Options") exercisable solely into common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") were granted under the Issuer's 2018 Equity Incentive Plan to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") in his capacity as a director of the Issuer. The Stock Options with a strike price of $62.50, vest on the earlier of June 8, 2021 or one day prior to the Issuer's next annual meeting following the grant date.

F2 · ownership.nature: Felix J. Baker serves on the board of directors of the Issuer (the "Board") as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds"). Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Felix J. Baker does not have any right to any of the Issuer's securities issued as part of his service on the Board and the Funds are entitled to receive all of the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the Stock Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options (i.e. no direct pecuniary interest).

F3 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001209191-20-035719 · doc4.xml · derivative · entry 1

PROFUSEK ROBERT · CIK 0001143732 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,135

Underlying: Common Stock · 4,135 shares

Expires 2030-06-07

F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 8, 2021 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date.

SEC source: 0001209191-20-035717 · doc4.xml · derivative · entry 1

Levy Richard S · CIK 0001454983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,135

Underlying: Common Stock · 4,135 shares

Expires 2030-06-07

F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 8, 2021 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date.

SEC source: 0001209191-20-035712 · doc4.xml · derivative · entry 1

Dahiyat Bassil I · CIK 0001591312 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,135

Underlying: Common Stock · 4,135 shares

Expires 2030-06-07

F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 8, 2021 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date.

SEC source: 0001209191-20-031755 · doc4.xml · derivative · entry 5

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 403,075

Underlying: Common Stock · 6,950 shares

Expires 2028-08-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vested on September 1, 2019 and 1/48th of the shares subject to the option vest on the same day of each month thereafter.

SEC source: 0001209191-20-031755 · doc4.xml · nonDerivative · entry 4

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,284

F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $61.18 to $62.10, inclusive.

SEC source: 0001209191-20-031755 · doc4.xml · nonDerivative · entry 3

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,374

F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $60.06 to $60.99, inclusive.

SEC source: 0001209191-20-031755 · doc4.xml · nonDerivative · entry 2

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,005

F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $58.72 to $59.705, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes.

SEC source: 0001209191-20-031755 · doc4.xml · nonDerivative · entry 1

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,234

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-025356 · doc4.xml · derivative · entry 6

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 410,025

Underlying: Common Stock · 6,950 shares

Expires 2028-08-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vested on September 1, 2019 and 1/48th of the shares subject to the option vest on the same day of each month thereafter.

SEC source: 0001209191-20-025356 · doc4.xml · nonDerivative · entry 5

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,284

F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $55.08 to $56.04, inclusive.

SEC source: 0001209191-20-025356 · doc4.xml · nonDerivative · entry 4

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,208

F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $54.03 to $55.03, inclusive.

SEC source: 0001209191-20-025356 · doc4.xml · nonDerivative · entry 3

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,044

F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $53.00 to $53.82, inclusive.

SEC source: 0001209191-20-025356 · doc4.xml · nonDerivative · entry 2

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,595

F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $51.98 to $52.75, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes.

SEC source: 0001209191-20-025356 · doc4.xml · nonDerivative · entry 1

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,234

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-024246 · doc4.xml · derivative · entry 6

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's common stock.

F7 · derivative.exercise_date: 50% of the RSU vested 12 months after October 9, 2018 (the "Grant Date"), 25% of the RSU vested 18 months after the Grant Date and 25% of the RSU vest 24 months after the Grant Date.

F7 · derivative.expiration_date: 50% of the RSU vested 12 months after October 9, 2018 (the "Grant Date"), 25% of the RSU vested 18 months after the Grant Date and 25% of the RSU vest 24 months after the Grant Date.

SEC source: 0001209191-20-024246 · doc4.xml · nonDerivative · entry 5

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,284

F3 · shares: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. These sales were made to cover tax withholding obligations in connection with vesting and settlement of 25% of the Reporting Person's RSU granted on October 9, 2018.

F6 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $49.29 to $49.83, inclusive.

SEC source: 0001209191-20-024246 · doc4.xml · nonDerivative · entry 4

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,201

F3 · shares: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. These sales were made to cover tax withholding obligations in connection with vesting and settlement of 25% of the Reporting Person's RSU granted on October 9, 2018.

F5 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $48.185 to $49.00, inclusive.

SEC source: 0001209191-20-024246 · doc4.xml · nonDerivative · entry 3

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,546

F3 · shares: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. These sales were made to cover tax withholding obligations in connection with vesting and settlement of 25% of the Reporting Person's RSU granted on October 9, 2018.

F4 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $47.095 to $48.045, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.

SEC source: 0001209191-20-024246 · doc4.xml · nonDerivative · entry 2

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,484

F2 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting and settlement of 25% of the Reporting Person's restricted stock units granted on October 9, 2018. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e).

SEC source: 0001209191-20-024246 · doc4.xml · nonDerivative · entry 1

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,542

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's common stock.

SEC source: 0001209191-20-023673 · doc4.xml · nonDerivative · entry 1

Liang Hong · CIK 0001754627 · SVP, Discovery Medicine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,166

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $41.97 to $42.71, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-023677 · doc4.xml · derivative · entry 1

Bancroft Charles A · CIK 0001480250 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,293

Underlying: Common Stock · 14,293 shares

Expires 2030-04-01

F1 · derivative.exercise_date: 1/3rd of the shares subject to the option vests on the first anniversary of the grant date and 1/36th of the shares subject to the option vest on each month thereafter on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month), in each case, provided that the Reporting Person continues to serve as a member of the Board through the applicable vesting date.

SEC source: 0001209191-20-021727 · doc4.xml · nonDerivative · entry 3

Liang Hong · CIK 0001754627 · SVP, Discovery Medicine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,166

F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.

SEC source: 0001209191-20-021727 · doc4.xml · nonDerivative · entry 2

Liang Hong · CIK 0001754627 · SVP, Discovery Medicine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,518

F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $47.88 to $48.78, inclusive.

SEC source: 0001209191-20-021727 · doc4.xml · nonDerivative · entry 1

Liang Hong · CIK 0001754627 · SVP, Discovery Medicine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,621

F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $46.84 to $47.84, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.